Maja Mockenhaupt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5552251/publications.pdf

Version: 2024-02-01

567281 454955 2,880 27 15 30 citations g-index h-index papers 32 32 32 2443 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study. Journal of Investigative Dermatology, 2008, 128, 35-44.	0.7	807
2	Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. Journal of the American Academy of Dermatology, 2008, 58, 25-32.	1.2	393
3	Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): Structure and results of a population-based registry. Journal of Clinical Epidemiology, 1996, 49, 769-773.	5.0	327
4	The current understanding of Stevens–Johnson syndrome and toxic epidermal necrolysis. Expert Review of Clinical Immunology, 2011, 7, 803-815.	3.0	237
5	Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatology, 2017, 153, 514.	4.1	235
6	EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 14-27.	5.7	149
7	Controversies in drug allergy: Testing for delayed reactions. Journal of Allergy and Clinical Immunology, 2019, 143, 66-73.	2.9	144
8	Guideline for the diagnosis of drug hypersensitivity reactions. Allergo Journal International, 2015, 24, 94-105.	2.0	139
9	Identification of drug-specific public TCR driving severe cutaneous adverse reactions. Nature Communications, 2019, 10, 3569.	12.8	83
10	Epidemiology of Staphylococcal Scalded Skin Syndrome in Germany. Journal of Investigative Dermatology, 2005, 124, 700-703.	0.7	80
11	<i>HLAâ€B*57:01</i> confers genetic susceptibility to carbamazepineâ€induced SJS/TEN in Europeans. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2227-2230.	5.7	51
12	SJS/TEN 2019: From science to translation. Journal of Dermatological Science, 2020, 98, 2-12.	1.9	41
13	Making a diagnosis in severe cutaneous drug hypersensitivity reactions. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 283-293.	2.3	38
14	New Evidence Supporting Cyclosporine Efficacy in EpidermalÂNecrolysis. Journal of Investigative Dermatology, 2017, 137, 2047-2049.	0.7	30
15	Fever in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Pediatric Cases. Pediatric Infectious Disease Journal, 2017, 36, 513-515.	2.0	29
16	Epidermal Necrolysis, Ocular Complications, and "Cold Medicines― Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 703-704.	3.8	15
17	Severe skin reactions: clinical picture, epidemiology, etiology, pathogenesis, and treatment. Allergo Journal International, 2019, 28, 311-326.	2.0	15
18	Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line. Dermatology and Therapy, 2022, 12, 381-393.	3.0	13

#	Article	IF	Citations
19	Evidence of involvement of CXC-chemokines in proliferation of cultivated human melanocytes. International Journal of Molecular Medicine, 2003, 12, 597-601.	4.0	11
20	Incidence of Epidermal Necrolysis: Results of the German Registry. Journal of Investigative Dermatology, 2020, 140, 2525-2527.	0.7	10
21	Radiation-Associated Pemphigus Vulgaris in a Patient With Preceding Malignancy: Treatment With Rituximab as a Valuable Option. Frontiers in Immunology, 2019, 10, 3116.	4.8	9
22	The case-crossover design via penalized regression. BMC Medical Research Methodology, 2016, 16, 103.	3.1	4
23	Drug Allergy and Cutaneous Adverse Reactions. Handbook of Experimental Pharmacology, 2021, 268, 195-212.	1.8	2
24	Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): Evaluation for drug risk based on sale numbers in defined daily doses (DDD). Example of the H2-antagonists. Pharmacoepidemiology and Drug Safety, 1995, 4, 207-212.	1.9	1
25	Effects of immunomodulating therapies on mortality in patients with severe cutaneous adverse reactions in comparison with supportive care only: a systematic review. Clinical and Translational Allergy, 2014, 4, P15.	3.2	1
26	Dr. Maja Mockenhaupt. Nishinihon Journal of Dermatology, 2019, 81, 217-218.	0.0	0
27	Epithelial Necrolysis. , 2021, , 409-422.		0